Gilead Announces Executive Promotions

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 28, 2015-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the promotion of Andrew Cheng, MD, PhD to Executive Vice President, HIV Therapeutics and Development Operations, and Taiyin Yang, PhD, to the role of Executive Vice President, Pharmaceutical Development and Manufacturing. Dr. Cheng and Dr. Yang will both join Gilead’s senior leadership committee.

Dr. Cheng joined Gilead in 1999. He has led clinical development activities for the company’s development-stage programs in HIV/AIDS. In 2009, he was appointed Senior Vice President, HIV Therapeutics and Development Operations, assuming additional responsibility for biometrics, clinical operations, clinical pharmacology, drug safety and public health, project management and regulatory affairs. Dr. Cheng reports to Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer. Prior to joining Gilead, Dr. Cheng trained in internal medicine at the University of California, Los Angeles. He received his medical degree and PhD in Cellular and Molecular Biology from Columbia University and his undergraduate degree from the Johns Hopkins University.

Dr. Yang joined Gilead in 1993 and was promoted to Senior Vice President in 2005. In her newly expanded role, Dr. Yang is responsible for managing pharmaceutical development, analytical operations, laboratory information, quality assurance and manufacturing of both clinical and commercial drug substance and drug product. She reports to Dr. Bischofberger and to John Milligan, PhD, President and Chief Operating Officer. Prior to joining Gilead, Dr. Yang was Director of Analytical Chemistry at Syntex. Dr. Yang received her bachelor’s degree in Chemistry from National Taiwan University and her PhD in Organic Chemistry from the University of Southern California.

“Andrew and Taiyin have both demonstrated leadership in bringing groups together to help expedite the development and manufacturing of products – ultimately allowing the company to reach patients in need more quickly,” commented Dr. Bischofberger. “They are experts in their respective fields and have helped build teams that are efficient and highly productive. These promotions recognize their achievements and dedication to bringing innovative new therapies to patients around the world.”

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.Gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Source: Gilead Sciences, Inc.

Gilead Sciences, Inc.
Patrick O’Brien, 650-522-1936 (Investors)
Amy Flood, 650-522-5643 (Media)